梓橦宫(832566) - 2023 Q3 - 季度财报

Financial Performance - Operating revenue for the first nine months of 2023 was CNY 296,228,981.20, representing a decrease of 7.67% compared to CNY 320,851,980.57 in the same period last year[11] - Net profit attributable to shareholders for the first nine months of 2023 was CNY 65,178,007.69, down 15.39% from CNY 77,030,024.60 year-on-year[11] - The company reported a total profit for the first nine months of 2023 of CNY 78,790,589.24, a decline of 17.6% from CNY 95,581,051.20 in 2022[42] - The company’s basic earnings per share for the first nine months of 2023 was CNY 0.44, down 16.98% from CNY 0.53 in the same period last year[11] - The total comprehensive income for the first nine months of 2023 was CNY 67,759,704.66, down from CNY 81,209,591.65 in 2022, reflecting a decrease of 16.5%[43] Cash Flow - The company reported a net cash flow from operating activities of CNY 73,555,281.08, a decline of 14.46% compared to CNY 85,986,262.81 in the previous year[11] - Operating cash flow for the first nine months of 2023 was ¥73,555,281.08, a decrease of 14.4% compared to ¥85,986,262.81 in the same period of 2022[44] - Total cash inflow from operating activities was ¥339,607,303.75, down from ¥361,636,044.22, reflecting a decline of 6.1% year-over-year[44] - Cash outflow from operating activities totaled ¥266,052,022.67, compared to ¥275,649,781.41 in 2022, indicating a decrease of 3.3%[44] - The ending cash and cash equivalents balance for the first nine months of 2023 was ¥59,867,885.71, compared to ¥107,570,895.91 at the end of 2022[45] Assets and Liabilities - Total assets as of September 30, 2023, reached CNY 846,986,868.49, a 0.57% increase from CNY 842,184,856.01 at the end of 2022[11] - Total liabilities increased to CNY 133,946,086.91 from CNY 130,319,447.71 year-over-year[32] - Non-current assets totaled CNY 302,561,664.12 as of September 30, 2023, compared to CNY 284,920,073.12 at the end of 2022, indicating growth of approximately 6.1%[32] - Current liabilities rose to CNY 79,504,111.61 from CNY 72,205,720.23, reflecting an increase of about 10.0%[32] - As of September 30, 2023, total current assets amount to 544,425,204.37 CNY, a decrease from 557,264,782.89 CNY at the end of 2022[30] Investments and Equity - Long-term equity investments increased by 37.33% to CNY 53,468,557.88, primarily due to capital contributions to affiliated companies[13] - The company's equity attributable to shareholders increased to CNY 709,193,704.39 from CNY 707,835,828.64[32] - The investment income for the first nine months of 2023 was CNY 6,074,096.94, an increase from CNY 5,665,481.68 in 2022, showing a growth of 7.2%[42] Research and Development - Research and development expenses decreased by 38.88% to CNY 5,853,104.09, as the company had no new R&D projects during the reporting period[13] - Research and development expenses decreased to CNY 4,139,904.21 in 2023 from CNY 8,256,805.37 in 2022, representing a reduction of 50%[42] Shareholder Information - The total number of unrestricted shares is 114,829,761, representing 78.35% of the total share capital[18] - The number of shares held by the largest shareholder, Tang Xi, is 32,925,730, accounting for 22.47% of the total shares[19] - The total number of shareholders holding more than 5% of shares is 10, with a combined holding of 67,092,681 shares, representing 45.78% of total shares[19] Other Information - The company has no ongoing litigation or arbitration matters during the reporting period[22] - The company has not disclosed any new commitments during the reporting period, and all previously disclosed commitments are being fulfilled[26] - The company completed the initial grant of 2.4 million restricted stock under the 2023 equity incentive plan at a grant price of 3.21 CNY per share[23] - The company repurchased 3 million shares using its own funds for the equity incentive plan, with the repurchase completed by July 5, 2023[24]

Sichuan Zitonggong Pharmaceuticals -梓橦宫(832566) - 2023 Q3 - 季度财报 - Reportify